Abstract
IntroductionObesity is a known risk factor for breast cancer. Sphingosine kinase 1 (SK1) is an oncogenic lipid kinase that is overexpressed in breast tumours and linked with poor prognosis, however, its role in obesity-driven breast cancer was never elucidated.MethodsHuman primary and secondary breast cancer tissues were analysed for SK1 and leptin receptor expression using quantitative real-time polymerase chain reaction (qRT-PCR) assay. Leptin-induced signalling was analysed in human oestrogen receptor (ER)-positive and negative breast cancer cells using Western blotting, qRT-PCR and radiolabelling assays.ResultsOur findings show for the first time that human primary breast tumours and associated lymph node metastases exhibit a strong correlation between SK1 and leptin receptor expression (Pearson R = 0.78 and R = 0.77, respectively, P <0.001). Both these genes are elevated in metastases of ER-negative patients and show a significant increase in patients with higher body mass index (BMI). Leptin induces SK1 expression and activation in ER-negative breast cancer cell lines MDAMB-231 and BT-549, but not in ER-positive cell lines. Pharmacological inhibition and gene knockdown showed that leptin-induced SK1 activity and expression are mediated by activation of extracellular signal-regulated kinases 1/2 (ERK1/2) and Src family kinase (SFK) pathways, but not by the major pathways downstream of leptin receptor (LEPR) - janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3). Src-homology 2 domain-containing phosphatase 2 (SHP2) appeared to be key to SK1 activation, and may function as an adaptor protein between SFKs and LEPR. Importantly, leptin-induced breast cancer cell proliferation was abrogated by SK1-specific small interfering RNA (siRNA).ConclusionsOverall, our findings demonstrate a novel SFK/ERK1/2-mediated pathway that links leptin signalling and expression of oncogenic enzyme SK1 in breast tumours and suggest the potential significance of this pathway in ER-negative breast cancer.Electronic supplementary materialThe online version of this article (doi:10.1186/s13058-014-0426-6) contains supplementary material, which is available to authorized users.
Highlights
Obesity is a known risk factor for breast cancer
Expression of leptin receptor (LEPR)-Long and Sphingosine kinase 1 (SK1) correlates in human breast tumours and metastatic lymph nodes, and is elevated in patients with high body mass index (BMI) We have used Taqman quantitative real-time polymerase chain reaction (qRT-PCR) to quantify LEPR-Long and SK1 expression in macrodissected paraffinised sections of breast tumours and corresponding LN metastases obtained from 69 patients
In oestrogen receptor (ER)-negative patients, SK1 and LEPR-Long expression was significantly higher in metastatic LNs than in primary tumours or LNs from ER-positive patients (Figure 1F)
Summary
Sphingosine kinase 1 (SK1) is an oncogenic lipid kinase that is overexpressed in breast tumours and linked with poor prognosis, its role in obesity-driven breast cancer was never elucidated. Obesity is a risk factor for poor breast cancer prognosis [2] and metastasis [3]; and oestrogen production and adipokine secretion were tagged as key elements in this relationship [2,3,4]. Leptin is one of the prominent adipokines and its intratumoural levels are positively correlated with poor breast cancer prognosis [5], advanced stage [3], metastasis and recurrence [6]. Leptin signalling triggers activation of extracellular signal-regulated kinases 1/2 (ERK1/2), STAT3, and phosphatidylinositol 3-kinase (PI3K)/Akt [9]. Leptin retains the ability to stimulate STAT3 and ERK1/2 in cells lacking JAK2 kinase, where JAK2independent responses appear to be mediated by members of the src family kinases (SFKs) [10]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.